LifeSci Capital Initiates Coverage of Ignyta, Inc.

Precision Medicine Company with Pipeline of Targeted Agents; Report Available here: www.lifescicapital.com/equity-research/ignyta/

NEW YORK, NY / ACCESSWIRE / May 29, 2015 / LifeSci Capital, LLC, a research-driven investment bank with deep domain expertise in the life sciences sector, today announced that it has initiated coverage of Ignyta, Inc. (NasdaqCM: RXDX), a precision medicine company developing oncology assets via an integrated drug and companion diagnostic approach known as Rx/Dx. Ignyta’s lead clinical candidate, entrectinib, is an oral, potential first-in-class tyrosine kinase inhibitor of TrkA, TrkB, TrkC, ROS1, and ALK. Entrectinib is currently being tested in two Phase I/II clinical studies.

Entrectinib (formerly RXDX-101) is an oral, potential first-in-class and best-in-class RTK inhibitor targeting TrkA, TrkB, TrkC, ROS1, and ALK. Trk receptors were identified as promising therapeutic targets through an extensive analysis and mining effort of Ignyta’s Oncolome(TM) database. The Company subsequently identified and in-licensed entrectinib from Nerviano Medical Sciences, a former Pfizer/Pharmacia cancer drug discovery site in Italy. No other Trk inhibitors are currently in Phase II or later stage clinical trials, despite a growing understanding of the presence of Trk alterations in many cancers such as lung, colorectal, and neuroblastoma. Ignyta recently expanded its pipeline by in-licensing 4 programs from Teva, substantially increasing the Company’s market opportunity, and allowing the use of an umbrella trial design going forward for more efficient drug testing.

In a 37 page Initiation Report LifeSci Capital explains the development path and clinical data for entrectinib in solid tumors. The report also describes the opportunity for cost effective development of multiple, targeted agents in tandem.

Dr. Isaacson’s full Initiation Report, including important disclosures, is available to download at no cost at the LifeSci Capital website, www.lifescicapital.com/equity-research/. In addition to this Initiation Report, LifeSci Capital intends to provide ongoing coverage and event-based research updates on Ignyta as developments occur.

The LifeSci Capital research team is led by Dr. Jerry Isaacson, an industry veteran with broad experience in biotechnology, having worked in both public and private biotech companies in areas ranging from medicinal chemistry and analytical chemistry to patents and investor/public relations. Dr. Isaacson holds a Bachelor of Arts degree in Chemistry from Harvard University and received his Ph.D. in Organic Chemistry from the University of California in San Diego.

About LifeSci Capital:

LifeSci Capital (Member: FINRA/SIPC) is a research-driven investment bank with deep domain expertise in the life sciences. Our service model as a boutique investment bank is unique in that we exclusively serve emerging life science companies that discover, develop, and commercialize innovative products. We view our clients as our partners, and we work closely with them to establish and execute their capital markets strategies. Our broadly-distributed equity research product is differentiated and provides a deep understanding of our clients’ businesses and the opportunities they are addressing. To learn more about LifeSci Capital, visit the company’s website, www.lifescicapital.com.

Analyst Contact:

Jerry Isaacson, Ph.D.
Phone: (646) 597-6991
Email: jisaacson@lifescicapital.com

SOURCE: LifeSci Capital

ReleaseID: 429371